Stone Ridge Asset Management LLC lifted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 11.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 134,885 shares of the biopharmaceutical company’s stock after purchasing an additional 13,900 shares during the period. Stone Ridge Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $6,117,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its holdings in shares of Bristol-Myers Squibb by 0.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,012,753 shares of the biopharmaceutical company’s stock worth $208,561,000 after purchasing an additional 35,653 shares during the period. Curbstone Financial Management Corp boosted its holdings in shares of Bristol-Myers Squibb by 14.8% in the 1st quarter. Curbstone Financial Management Corp now owns 14,392 shares of the biopharmaceutical company’s stock worth $687,000 after purchasing an additional 1,850 shares during the period. 6 Meridian boosted its holdings in shares of Bristol-Myers Squibb by 27.7% in the 1st quarter. 6 Meridian now owns 280,913 shares of the biopharmaceutical company’s stock worth $13,402,000 after purchasing an additional 60,871 shares during the period. Gateway Investment Advisers LLC boosted its holdings in shares of Bristol-Myers Squibb by 2.0% in the 1st quarter. Gateway Investment Advisers LLC now owns 841,460 shares of the biopharmaceutical company’s stock worth $40,146,000 after purchasing an additional 16,541 shares during the period. Finally, Pacer Advisors Inc. purchased a new position in Bristol-Myers Squibb during the 1st quarter valued at $6,954,000. Institutional investors and hedge funds own 80.11% of the company’s stock.
NYSE BMY traded down $1.28 on Friday, reaching $46.58. 13,584,015 shares of the stock traded hands, compared to its average volume of 13,780,662. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. The company has a fifty day moving average price of $45.53 and a 200-day moving average price of $47.40. The company has a market cap of $78.14 billion, a price-to-earnings ratio of 11.70, a PEG ratio of 2.36 and a beta of 0.73. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $63.69.
The company also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 3.52%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.
A number of equities analysts recently issued reports on BMY shares. Argus cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective for the company. in a report on Monday, May 20th. UBS Group dropped their price objective on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating for the company in a report on Thursday, June 13th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Tuesday, May 7th. Barclays upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $53.00 to $55.00 in a report on Friday, May 3rd. Finally, Atlantic Securities upgraded Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective for the company in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $55.88.
In other news, Director Robert J. Bertolini bought 11,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was acquired at an average cost of $44.72 per share, with a total value of $491,920.00. Following the transaction, the director now directly owns 11,397 shares in the company, valued at approximately $509,673.84. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Recommended Story: What Factors Can Affect Return on Equity?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.